Sort
10,766 grants matching “checkpoint inhibitor”
Development Therapeutics Branch Clinical Trials
$179,137Yves Pommier · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Clinical evaluation of combination oncolytic viro-immunotherapy for solid tumors
$178,985Rosa Maria Diaz · Vyriad, Inc. · R44 · FY2018 · CA
Understanding how mitotic kinases drive EMT in breast cancers
$178,948Harold I Saavedra · Ponce School Of Medicine · U54 · FY2018 · CA
Engaging Impactful Immunotherapy Approaches in Renal Cell Cancer Studies
$178,893Naomi B Haas · University Of Pennsylvania · R50 · FY2025 · CA
Bispecific drug-conjugates for treating colorectal cancer
$178,843Kendra S. Carmon · University Of Texas Hlth Sci Ctr Houston · R21 · FY2024 · CA
SR-A as a therapeutic target in breast cancer
$178,819Behjatolah Monzavi Karbassi · Univ Of Arkansas For Med Scis · R21 · FY2025 · CA
Mechanisms of Th17-DC immunotherapy for ovarian cancer
$178,819Martin J Cannon · Univ Of Arkansas For Med Scis · R21 · FY2025 · CA
Patient-Specific Mutation-Derived Tumor Neoantigens as Targets for Cancer Immunotherapy in Smoldering Multiple Myeloma
$178,800Samir Parekh · Icahn School Of Medicine At Mount Sinai · R21 · FY2019 · CA
Project 2: Intratumoral PDT Induces PDP-based Enhancement of PD-1 Inhibition in Pancreatic Carcinoma
$178,337Kenneth K Wang · Massachusetts General Hospital · P01 · FY2024 · CA
Yale SPORE in Skin Cancer
$178,320Marcus W Bosenberg · Yale University · P50 · FY2022 · CA
Preclinical development of CXCR6 antagonists to target sorafenib resistance in Hepatocellular Carcinoma
$178,234Siobhan Malany · University Of Florida · R21 · FY2022 · CA
Understanding how mitotic kinases drive EMT in breast cancers
$178,099Harold I Saavedra · Ponce School Of Medicine · U54 · FY2017 · CA
Targeted Therapy for Endometrial Cancer
$178,025Kimberly K Leslie · University Of Iowa · R01 · FY2021 · CA
Ex vivo generation of tumor-reactive T cells for adoptive cell transfer using an immune enhanced, patient derived tumor organoid-on-a-chip (iTOC)
$177,924Aleksander Skardal · Ohio State University · R21 · FY2023 · CA
IMMUNOBIOLOGY OF MALIGNANT GLIOMA
$177,876Gavin Peter Dunn · Washington University · K08 · FY2017 · NS
IMMUNOBIOLOGY OF MALIGNANT GLIOMA
$177,876Gavin Peter Dunn · Washington University · K08 · FY2019 · NS
IMMUNOBIOLOGY OF MALIGNANT GLIOMA
$177,876Gavin Peter Dunn · Washington University · K08 · FY2018 · NS
Project 2: Transcriptional Dynamics and Temporal Reprogramming During Radiation Treatment
$177,762Jacob Gardinier Scott · Cleveland Clinic Lerner Com-Cwru · U54 · FY2023 · CA
Cancer Molecular Imaging, Nanotechnology and Theranostics
$177,678Johannes Czernin · University Of California Los Angeles · P30 · FY2022 · CA
Cancer Molecular Imaging, Nanotechnology and Theranostics
$177,678Johannes Czernin · University Of California Los Angeles · P30 · FY2024 · CA
Cancer Molecular Imaging, Nanotechnology and Theranostics
$177,678Johannes Czernin · University Of California Los Angeles · P30 · FY2021 · CA
Cancer Molecular Imaging, Nanotechnology and Theranostics
$177,678Johannes Czernin · University Of California Los Angeles · P30 · FY2023 · CA
Special Public T Cell Receptor Sequences that Predict Outcomes for Cancer Patients
$177,650Seth M Pollack · Northwestern University At Chicago · R21 · FY2024 · CA
Mechanisms of anti-tumor activity of group A Streptococcus in pancreatic adenocarcinoma
$177,650Brian A Boone · West Virginia University · R21 · FY2022 · CA
Role of Sirt2 in T Cell Metabolism
$177,605Sungjune Kim · Mayo Clinic Jacksonville · R37 · FY2023 · CA